

4415 words

Title: Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up.

Authors: Nicholas **Bussiere**^{1,2}; Jie **Mei**¹, PhD; Cindy **Levesque-Boissonneault**¹, MSc; Mathieu **Blais**³, PhD; Sara **Carazo**^{3,6}, MD, PhD; Francois **Gros-Louis**^{3,4}, PhD; Robert Jr **Laforce**^{3,7}, MD, PhD; Gaston **De Serres**^{3,5,6}, MD, PhD; Nicolas **Dupre**^{3,7}, MD, MSc, FRCP FAAN; Johannes **Frasnelli**¹, MD

¹ Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

² Faculty of Medicine, Université de Montréal, Montréal, QC, Canada

³ Centre Hospitalier Universitaire de Québec – Université Laval, Québec City, QC, Canada

⁴ Faculty of Medicine, Department of Surgery, Université Laval, Québec City, QC, Canada

⁵ Faculty of Medicine, Department of Social and Preventive Medicine, Université Laval, Québec City, QC, Canada

⁶ Institut National de Santé Publique du Québec, Québec City, QC, Canada

⁷ Faculty of Medicine, Department of Medicine, Université Laval, Québec City, QC, Canada

Correspondence to be sent to:

Johannes Frasnelli MD,
Université du Québec à Trois-Rivières,
3351, boul. des Forges, C.P. 500,
Trois-Rivières, QC G9A 5H7 Canada
Email: johannes.a.frasnelli@uqtr.ca

Abstract

Olfactory and gustatory dysfunctions (OD, GD) are prevalent symptoms following COVID-19 and persist in 6%-44% of individuals post-infection. As only few reports have described their prognosis after 6 months, our main objective was to assess the prevalence of OD and GD 11 months post-COVID-19. We also aimed to determine intraclass correlation coefficients (ICC) of chemosensory self-ratings for the follow-up of chemosensory sensitivity.

We designed an observational study and distributed an online questionnaire assessing chemosensory function to healthcare workers with a RT-PCR confirmed SARS-CoV-2 infection 5 and 11 months post-COVID-19. Specifically, we assessed olfaction, gustation, and trigeminal sensitivity (10-point visual analog scale) and function (4-point Likert scale). We further measured clinically relevant OD using the Chemosensory Perception Test, a psychophysical test designed to provide a reliable remote olfactory evaluation.

We included a total of 366 participants (mean (SD) age of 44.8 (11.7) years old). They completed the last online questionnaire 10.6 months (0.7) after the onset of COVID-19 symptoms. Of all participants, 307 (83.9%) and 301 (82.2%) individuals retrospectively reported lower olfactory or gustatory sensitivity during the acute phase of COVID-19. At time of evaluation, 184 (50.3%) and 163 (44.5%) indicated reduced chemosensory sensitivity, 32.2% reported impairment of olfactory function while 24.9% exhibited clinically relevant OD. Olfactory sensitivity had a high test-retest reliability (ICC: 0.818 (95% CI: 0.760 - 0.860)).

This study suggests that chemosensory dysfunctions persist in a third of COVID-19 patients 11 months after COVID-19. OD appears to be a common symptom of post-COVID-19 important to consider when treating patients.

Keywords: COVID-19, olfaction, gustation, trigeminal, parosmia, observational study.

Introduction

The COVID-19 pandemic has been ongoing for over two years, and many advances have been made to further understand its pathogenesis and treatment (Aimrane et al. 2022, NIH 2022). The high rate of post-COVID-19 olfactory dysfunction (OD) has brought interest to the field of post-viral OD, yet many questions remain unanswered regarding the duration and pathophysiology of this symptom (Havervall et al. 2021). Even before the pandemic, viral infections of the upper respiratory tract (URTI) were known to be a major cause of OD (Temmel et al. 2002). For patients with persisting OD, impairment may be quantitative (e.g., anosmia, hyposmia) and/or qualitative (e.g., parosmia, phantosmia) (Welge-Lussen et al. 2006). Both forms of OD may significantly decrease quality of life (QoL), and this impact gets worse as OD persists (Croy et al. 2014).

Initial presentation of COVID-19-induced OD is now well described: sudden loss affecting 50% to 75% of infected individuals (Xydakis et al. 2021). For most individuals, quantitative OD is predominant, but some have reported parosmia (altered perception of real stimuli) and/or phantosmia (perception of odor in absence of stimuli) in the acute phase (Islek et al. 2021, Kopishinskaia et al. 2021). Some individuals also present with other chemosensory alterations, such as gustatory dysfunction (GD; altered ability to taste sweet, sour, salty, bitter or umami) or trigeminal dysfunction (TD; altered ability to perceive spiciness, freshness, carbonation) (Parma et al. 2020, Tong et al. 2020, Mehraeen et al. 2021). Although most patients do recover within weeks from these dysfunctions, many remain symptomatic and their condition evolves into long-haul COVID-19 (Hopkins et al. 2020, Ferenzi et al. 2021). Six months after onset of symptoms, 5% to 60% of patients suffer from persistent OD and 10 to 35% have persistent GD (Hopkins et al. 2021, Lechien et al. 2021, Petrocelli et al. 2021). Few studies reported prevalence of TD, although a recent study which used psychophysical tests found a correlation between OD and TD at 6 months following a confirmed SARS-CoV-2 infection (Otte et al. 2022). This study could not establish a prevalence of trigeminal dysfunction due to their testing methods. Moreover, prevalence of parosmia increases with time in COVID-19 patients, which is in line with the theory that qualitative dysfunctions following viral infection could result from faulty regeneration of olfactory sensory neurons (Schwob et al. 2017, Schwob et al. 2020, Ohla et al. 2021). As described in a previous report, 52%, 42% and 23% of a cohort of healthcare workers with mild COVID-19 experienced OD, GD, and TD respectively at 5 months after onset of COVID-19 (Bussiere et al. 2021). For other viruses, recovery of postviral OD can be expected in up to 80% one year following

onset of infection (Lee et al. 2014). Therefore, long-term follow-up of patients is necessary to further understand the evolution of post-COVID-19 OD and eventually offer resources for clinicians and patients alike.

Although many patients with long-haul COVID-19 have persistent OD, very few studies describe the prognosis for such individuals past 6-months after symptom onset. Among these, approximately 25 to 30% of individuals suffer from persistent subjective OD one year after COVID-19 (Boscolo-Rizzo et al. 2022a, Fortunato et al. 2022). Some groups have also compared prevalence of objectively measured OD in COVID-19 patients and controls, finding higher prevalence of OD, GD and TD in the former group also one year after COVID-19 (Boscolo-Rizzo et al. 2021, Vaira et al. 2021b). However, a gap exists between subjectively reported OD and prevalence measured with psychophysical tests.

We followed up a cohort of healthcare workers with a PCR confirmed SARS-CoV-2 infection between 12 February and 11 June 2020, who consented to fill an online questionnaire and to self-report measurements from the Chemosensory Perception Test (CPT), a novel and easy to use olfactory test. Data for the first questionnaire from this cohort is published elsewhere (Bussiere et al. 2021). This present manuscript therefore compares data obtained at the first (mean: 4.9 months; range: 3-7 months) and the second (mean 10.6; range: 9 to 13 months) session collected from the same cohort (Bussiere et al. 2021). We will refer to the questionnaires from the first and second session as the 5- and 11-month questionnaires respectively to alleviate the text.

We had three specific objectives for this study: first, we aimed to determine the percentage of individuals who experience OD, GD, or TD 11 months after COVID-19. To do so, we used three different approaches to grasp different aspects of chemosensory dysfunction. Specifically, we assessed (a) the proportion of participants who indicated chemosensory sensitivity below levels prior to the infection (persistent reduction of chemosensory sensitivity); (b) the proportion of participants who indicated chemosensory function was much or a bit worse than before the infection (impairment of chemosensory function); (c) the proportion of participants who had a result indicative of dysfunction in a semi-objective test (clinically relevant OD). Second, we aimed at identifying the factors that best predict olfactory dysfunction 11.3 months after COVID-19. Third, we aimed to determine the test-retest reliability of subjective chemosensory ratings.

Methods:

Standard protocol approvals, registrations, and patient consents

This study was reviewed and approved by the research ethics board of the CHU de Québec – Université Laval (MP-20-2021-5228) and all protocols were reviewed by an independent Scientific Review Committee. This study complies with the Declaration of Helsinki for Medical Research involving Human Subjects. All participants provided an online informed consent prior to participation. The study received funding from the Fonds de recherche du Québec – Santé (FRQS). No compensation or incentive was offered to participants.

Participants

Healthcare workers with a positive SARS-CoV-2 PCR test were recruited among those who had completed the initial online questionnaire at 5 months after onset of symptoms. Inclusion criteria were (1) completed the follow-up online questionnaire (2) did not report other respiratory diseases (bacterial or viral infection) within 2 weeks prior to questionnaire completion, chronic sinusitis, or traumatic brain injury, and (3) did not have a symptomatic SARS-CoV-2 reinfection (Figure 1).

Study design

Data were collected from March 1 to April 27, 2021. Up to four attempts were made via email to reach and recruit potential participants.

Online questionnaire

All participants were invited to complete an online questionnaire as introduced earlier (Bussiere et al. 2021). The questionnaire comprised items on chemosensory self-assessment including demographic data, changes to medical history (based on the follow-up questionnaire of the Global Consortium on Chemosensory Research (Parma et al. 2020, Cecchetto et al. 2021)). Finally, we remotely administered the CPT, a semi-objective test for chemosensory function (Bussiere et al. 2021) (Supplementary Material 1). Participants were able to choose to fill out the questionnaire in French or English.

Chemosensory self-assessment

Here, participants were asked to self-evaluate and report their olfactory (*i.e., the ability to perceive the smell of flowers, soap, or garbage but not the flavor of food in the mouth*), gustatory (*i.e., the ability to perceive sweetness, sourness, saltiness, bitterness in the mouth*), and trigeminal (*i.e., the ability to perceive the spiciness of chili peppers, the cooling of menthol and the carbonation in soda*) sensitivity using a 10-point visual analog scale (VAS) at four time points: (T0) before SARS-

CoV-2 infection (i.e. baseline), (T1) during SARS-CoV-2 infection, (T2) at initial questionnaire completion (approximately 5 months after SARS-CoV-2 infection) and (T3) at last questionnaire completion (approximately 11 months after SARS-CoV-2 infection). This allowed us to determine if the individual subjectively exhibited full recovery; when a participant rated their current (at T3) ability to be lower than their self-evaluation at baseline (at T0; i.e.: $T3 < T0$), they were classified as exhibiting (a) persistent reduction of chemosensory sensitivity. In addition, these data also allowed us to compare scores from one timepoint to another (i.e.: T0 vs T2 vs T3). This set of questions was repeated from the first questionnaire.

Participants were then asked to compare their current (at T3) chemosensory function with those prior to the SARS-CoV-2 infection (T0), for which they may choose one of the following statements: (1) *much worse*, (2) *a bit worse*, (3) *the same*, (4) *a bit better*, and (5) *much better*. This set of questions was not present in the first questionnaire. Participants from categories (1) and (2) were classified as exhibiting (b) impairment of chemosensory function. For participants with self-reported OD or GD, we also collected information about the presence of current parosmia/phantosmia or alterations in the 5 taste qualities (i.e., sweet, salty, sour, bitter, umami) respectively. Qualitative changes in olfaction and gustation were asked for in both questionnaires.

Chemosensory Perception Test (CPT)

Finally, we remotely administered the CPT. This olfactory test requires participants to smell specific household substances (peanut butter, jam, coffee) and report the perceived intensity of each on a 10-point VAS (Bussiere et al. 2021). Scores were obtained by calculating the mean score reported for the 3 substances. Based on earlier data, we classified participants with a score lower or equal to 7 as exhibiting (c) clinically relevant OD (Bussiere et al. 2021). This test was conducted following both questionnaires.

Statistical Analysis

We used a custom Python script (Python 3.7.5, Python Software Foundation, <https://www.python.org>) and SPSS 26.0 (Armonk, NY: IBM Corp) to process raw questionnaire data. We used the Python script to merge results from the two questionnaires and SPSS Syntax to transform raw data. We analyzed and visualized processed data with SPSS 26.0, GraphPad Prism 8.3.1 (GraphPad Prism Software, San Diego, CA) and Raincloud plots (Allen et al. 2021).

We performed student's T-tests and chi square tests to assess change in (a) chemosensory sensitivity, prevalence of (b) persistent reduction of chemosensory sensitivity and of (c) clinically

relevant OD from T2 to T3. To quantify the effects of COVID-19 on *chemosensory modality* (olfactory, gustatory, and trigeminal sensitivity) and *time point* (T0, T1, T2, T3), we computed repeated measures (rm) ANOVA with age as a covariate using answers from the second questionnaire only. To disentangle interactions, we carried out separate rmANOVA out for individual chemosensory modalities and at T3 for the same factors. We used Greenhouse-Geisser corrections for sphericity and performed Tukey's multiple comparisons tests for post-hoc comparisons.

To determine differentiating characteristics between patients with and without impairment of chemosensory function at T3 after COVID-19 among those with reduction of chemosensory sensitivity during COVID-19, we performed a forward selection logistic regression to ascertain the effects of (1) age, (2) sex, (3) self-rated olfactory function at T0 as answered in the first questionnaire, (4) COVID-19 symptoms at T1 (fever, cough, dyspnea, chest pain, rhinorrhea, changes in food flavour, appetite loss, headache, myalgia, fatigue, diarrhea, abdominal pain, nausea; all reported in the first questionnaire), (5) chronic comorbidities with a prevalence of more than 5% in our sample (hypertension, obesity) and (6) qualitative OD (parosmia, phantosmia, waxing and waning) at T2 as reported in the first questionnaire, on the likelihood of impairment of chemosensory function at T3 (only reported in the second questionnaire). We did not include other chronic comorbidities in the model due to presence of these conditions in less than 5% of our population (heart disease, diabetes mellitus, pulmonary disease, neurological disease, cancer). We also excluded self-rated olfactory function at T1 from the model since it violated the assumption of linearity of the log odds.

Finally, subjective scales have been used widely in questionnaires to quantify the degree of COVID-19-related OD, yet few studies have analyzed the reliability of such measures in the context of the COVID-19 pandemic (Haxel et al. 2012, Parma et al. 2020, Prajapati et al. 2020, Biadsee et al. 2021). Measures of chemosensory sensitivity from T0 to T2 were repeated at the 5-month and 11-month questionnaires and compared to determine the test-retest reliability of self-evaluation (complete data set for 276 participants). To assess the intra-rater reliability of self-reported chemosensory ratings, we calculated intraclass correlation coefficients (ICC) and their 95% confidence intervals (CI) based on a mean rating ($k=2$), absolute agreement, two-way mixed-effects model. The ICC ranges from 0.00 (absence of reliability) to 1.00 (perfect reliability). No standard values exist for acceptable reliability using ICC, but generally, values below 0.50 indicate

poor reliability, between 0.50 and 0.75 indicate moderate reliability, between 0.75 and 0.90 indicate good reliability and above 0.90 is excellent reliability (Koo et al. 2016).

For all statistical tests, we set the alpha type error was set at 0.05. We expressed all results as mean and standard deviation (SD) unless otherwise specified.

Results:

Study population

We included a total of 366 healthcare workers in this study. The average age was of participants was of 44.8 years old (SD: 11.7). Among them, 310 (84.7%) were women, and the majority (83.1%) were Caucasian. On average, participants completed the online questionnaire 10.6 months (SD: 0.7, range: 8.9 - 13.0) after the onset of COVID-19 symptoms. During the acute SARS-CoV-2 infection (T1), 307 (83.9%) and 301 (82.2%) reported lower olfactory and gustatory scores respectively compared to T0. Our study population had a higher prevalence of OD and GD than the initial survey from which our participants were recruited (OD: $\chi^2(1, N= 4908) = 52.62$, $P < .001$); GD: $(\chi^2(1, N= 4908) = 68.03, P < .001)$ (Table 1).

Self-rated chemosensory sensitivity

Average self-evaluated olfactory sensitivity at T3 was 7.6 (2.2), compared to 9.1 (1.1) at T0; a total of 184 participants (50.3%) indicated persistent reduction of olfactory sensitivity. Average self-evaluated gustatory sensitivity was 8.0 (2.0) at T3, compared to 9.2 (1.5) at T0; a total of 163 participants (44.5%) indicated persistent reduction of gustatory sensitivity. Average self-evaluated trigeminal sensitivity was 8.7 (1.7) at T3, compared to 9.0 (1.7) at T0; a total of 86 (23.5%) indicated persistent reduction of trigeminal sensitivity.

Among 276 participants who had provided self-ratings at T2 and T3, the proportion of participants with persistent reduction of olfactory, gustatory, or trigeminal sensitivity did not change between T2 and T3 (olfaction: $\chi^2(1, N=276) = 2.62, P = .11$; gustation: $\chi^2(1, N=276) = 0.007, P = .93$; trigeminal: $(\chi^2(1, N=276) = 0.01, P= 0.92)$). However, olfactory ($t(275) = -3.91, P < .001$, 11 months $>$ 5 months), but not gustatory ($t(275) = -.673, P = .501$) or trigeminal ($t(275) = -.798, P = .425$) scores increased from 5 months to 11 months (Figure 2).

In fact, *chemosensory modality* ($F(2, 726) = 24.571, P < .001, \eta^2 = .063$; olfactory scores $<$ gustatory scores $<$ trigeminal scores; all $P < .001$) and *time point* ($F(3, 1089) = 48.88, P < .001, \eta^2 = .119$; T1 scores $<$ T2 scores $<$ T3 scores $<$ T0 scores, all $P < .001$) had an effect on self-ratings

(Figure 3). More specifically, the effect of *time point* was the strongest for olfactory ratings ($F (3, 1089) = 61.677, P < .001 \eta^2 = .145$; $T1 < T2 < T3 < T0$, all $P < .001$), followed by gustatory ratings ($F (3, 1089) = 48.654, P < .001, \eta^2 = .118$; $T1 < T2 < T3 < T0$, all $P < .001$), indicating that these two modalities evolve the most in time. For the trigeminal function, *time point* also influenced self-ratings, but the average self-rating at T3 was comparable to that of T0 ($F (3, 1089) = 3.506, P = .028 \eta^2 = .010$; $T1 < T2 < T3$ (all previous $P < .001$) = T0 (T3 vs T0: $P = .060$)), indicating a return to baseline trigeminal function.

Subjective impairment of chemosensory function

When asked to compare T3 with T0, 118 (32.2%; 50 (13.7 %): much worse; 68 (18.6%): a bit worse) participants reported persistent impairment of olfactory function, 111 (30.3%) (29 (7.9%): much worse; 82 (22.4%): a bit worse) persistent impairment of gustatory function and 52 (14.2%) (9 (2.5 %): much worse; 43 (11.7%): a bit worse) reported persistent impairment of trigeminal function (Figure 4).

Among 118 participants with persistent impairment of olfactory function, a total of 68 (56.7%), 33 (28.0%) and 27 (22.9%) reported parosmia, phantosmia or waxing and waning, respectively at T3. One participant reported persistent nasal congestion, while 2 participants could not describe the qualitative impairment. At T2, 20 (16.9%), 27 (22.9%) and 21 (17.8%) had reported parosmia, phantosmia or waxing and waning, respectively.

Among the 111 participants who reported worsened gustatory function at T3, bitter taste was the most affected quality (46.8%), followed by sweet (40.5%), salty (38.7%), umami (33.3%), and sour (32.4%). Among them, 9.9% report a combined gustatory dysfunction involving all 5 taste qualities.

Clinically relevant olfactory dysfunction

A total of 91 (24.9%) participants exhibited CPT scores equal or less than 7 indicating clinically relevant OD at T3. Although this number was nominally down from 108 (29.5%) at T2, there was no difference in the proportions between both time points ($\chi^2 (1, N = 366) = 1.93, P = .16$). Nevertheless, the average CPT score significantly increased by 0.45 points from T2 (6.9 points) to T3 (7.3 points).

Association between measures

Prediction of persistent impairment of olfactory function

The logistic regression model was statistically ($\chi^2(3, N= 307) = 30.77, P < .001$) to predict persistent impairment of olfactory function; sensitivity and specificity of the model were respectively of 0.92 and 0.21. Three variables were significantly associated with a higher likelihood of persistent impairment of olfactory function 11 months after COVID-19 (Table 2), namely (1) chest tightness at T1 (during infection), (2) dysgeusia at T1 (during infection), and (3) presence of phantosmia at T2 (5 months after infection).

Test-retest reliability of subjective chemosensory ratings

Self-ratings from the first and second questionnaires correlated significantly at each of three repeated time points (T0, T1, and T2), and olfaction had the highest correlation coefficients. Notably, for olfaction, the average-measures of the ICC were 0.635 (95 % CI: 0.552 - 0.703), 0.927 (0.908 - 0.941) and 0.818 (95% CI: 0.760 - 0.860), respectively, for T0, T1 and T2 indicating high test-retest reliability. Gustation (T0: 0.332 (0.180 – 0.456); T1: 0.809 (0.865 - 0.910); T2: 0.661 (0.494 - 0.764)) and trigeminal function (T0: 0.388 (0.248 - 0.502); T1: 0.607 (0.515 - 0.681); T2: 0.320 (0.143 - 0.461)) had somewhat lower test-retest reliability (Table 3).

Discussion

This study was carried out 11 months after RT-PCR-confirmed SARS-CoV-2 infection and revealed three major results. First, we found that a considerable proportion of participants still exhibited chemosensory loss of different degrees. Specifically, (a) we observed persistent reduction of olfactory (gustatory, trigeminal) sensitivity in 50% (45%, 24%) of participants, i.e., ratings had not yet returned to levels before the infection; (b) roughly a third of participants exhibited persistent olfactory and gustatory impairment; this was one out of seven for the trigeminal system; (c) roughly one quarter of participants had test scores indicative of clinically relevant OD. Second, we observed that presence of (a) chest tightness and (b) subjective dysgeusia during COVID-19 as well as (c) presence of phantosmia at 5 months were predictors for persistent olfactory impairment at 11 months. Third, we observed that the measures we used exhibited good test-retest reliability, especially for olfactory measures.

Our sample roughly exhibited 20% higher rates of reduced olfactory and sensitivity during the acute phase of COVID-19 than the initial survey respondents. Therefore, OD and GD prevalence reported from this study are probably overestimated, but it would be difficult to

determine exactly how the recovery rates might differ from participating and non-participating individuals. 32% of participants exhibited persistent OD and 25% exhibited a CPT score indicating clinical OD. The prevalence of parosmia in individuals with post-COVID-19 OD has been reported to be in the range of 7% to 93% in varying degrees of severity (Parma et al. 2020, Hopkins et al. 2021). In this cohort, prevalence of parosmia was at 17% at 5 months after the infection and rose to over 50% at 11 months (Bussiere et al. 2021). This is in line with a recent study that reported increasing incidence of parosmia in individuals recovering from long-haul COVID-19 (Ohla et al. 2021). This finding is particularly important, as parosmia has been associated with a better olfactory outcome following olfactory training, but if unresolved, it may be a much greater source of distress than isolated hyposmia (Muller et al. 2006, Liu et al. 2021). Further, an important proportion of COVID-19 patients also reported phantosmia and waxing and waning of olfactory function, although these chemosensory dysfunctions have not been associated with a better outcome (Reden et al. 2007). These qualitative changes could indicate ongoing modifications in the olfactory epithelium or in higher order processing networks (Leopold 2002, Iannilli et al. 2019). Among all participants, olfactory function measured with a semi-objective test nominally increased between 5 months and 11 months; yet no significant difference was found in OD prevalence at 5 and 11 months using this tool. This could be interpreted as an increase in qualitative disorders combined with improved olfactory sensitivity, or lower spontaneous recovery rates for those with more severe deficits while others with milder and clinically irrelevant forms continue to recuperate.

We found that 30% of the participants in the cohort exhibited persistent GD, with bitter as the most affected taste quality. One study on taste thresholds in COVID-19 patients found that the threshold was increased for sweet, sour and bitter, but they were decreased for salty in the acute phase (Asadi et al. 2021). Individuals with taste dysfunction have also reported qualitative taste alterations such as phantogeusia and parageusia (Ercoli et al. 2021). TD at 11 months was reported by less than 15% of participants. According to a recent study, impaired trigeminal function could play a role in local inflammatory response, which may in turn influence recovery (Cecchetto et al. 2021).

We explored chemosensory alterations in three different ways: A relatively high number of individuals reported at least slight alterations in chemosensitivity compared to baseline when using VAS ratings. When directly asked if a given chemical sense was a bit worse or much worse

compared to baseline, a smaller number of individuals self-reported dysfunction. Therefore, even though a large proportion of individuals with post-COVID-19 chemosensory alterations might feel like their senses are not back to normal, only some of these have more severe dysfunctions. The CPT could have allowed for a more precise self-evaluation of olfaction, as participants had to use their sense of smell and immediately reflect on their performance in perceiving odors. Therefore, participants might believe their sense of smell was inferior to what they remembered it used to be (subjective OD), when presented with a smell on which to focus, some participants would rate their perception to be functional enough. The CPT does have its limitations, especially when administered to normosmic or very slightly hyposmic individuals {Bussiere, 2021 #108}. In the clinical setting, it is imperative that clinicians use the same scale or measure if they wish to follow-up subjective olfactory complaints as the answer may vary depending on the formulation of the question.

Few clinical measures proved to be good indicators of olfactory prognostic following COVID-19-induced OD, in line with other reports (Saussez et al. 2021a, Coelho et al. 2022). In our study, presence of (a) chest tightness and (b) taste disorders during acute COVID-19 as well as (c) presence of phantosmia at 5 months were significantly associated with a higher chance of persisting OD at 11 months. The links between these variables remain speculative. Chest tightness may indicate a more severe form of COVID-19, although OD was not associated with a more severe course of COVID-19, nor were the other symptoms indicative of more severe COVID-19 (associated with persistence of OD (abdominal pain, dyspnea, anorexia, diarrhea, or fatigue) (Foster et al. 2020, He et al. 2020, Mudatsir et al. 2020). We do not have data on hospitalization rates in this cohort to accurately assess severity of the disease. Participants may mistake lack of flavor perception due to reduced retronasal olfaction caused by OD as taste problems in the acute phase of COVID-19 (Spence 2015, Kakutani et al. 2017, Liu et al. 2020). This finding could either be due to more severe olfactory loss being related to longer duration of the symptom, or that GD does influence olfactory recovery by unknown mechanisms. Finally, although the pathomechanism of phantosmia is still unknown, one could expect that a more severe inflammatory reaction in the olfactory cleft may cause phantosmia and could take more time to recover (Eliezer et al. 2020). One study found patients with lower levels of salivary and nasal immunoglobulins G at 60 days post-infections had worse olfactory outcomes, which hints to local inflammation as an important factor in persistence of OD (Saussez et al. 2021a). Accordingly, we

found that the presence of phantosmia increased the likelihood of OD persistence. While this further suggests a role of immune local response in the evolution of persistent chemosensory disorders, more research must be conducted to accurately identify patients with a better chance of olfactory recovery. More studies will be required to validate the link between these variables, especially between qualitative OD and olfactory recovery. Meanwhile, clinicians can only continue to encourage their patients with persisting OD to try olfactory training and/or intranasal corticosteroid sprays following resolution of the infection (Huart et al. 2021, Saussez et al. 2021b, Vaira et al. 2021a).

Olfactory subjective ratings had a very good test-retest reliability in our study population. Psychophysical evaluations do remain the ideal method to measure all chemosensory disorders but the use of a 10-point VAS may have some value in monitoring OD, especially in large populations or in a social distancing setting. Previous studies have found self-ratings of olfactory function to have a poor reliability and low correlation with objective testing (Lotsch et al. 2019). However, our findings suggest self-ratings could be a good alternative for clinicians with limited time or a difficult access to objective testing. These findings can be explained in the context of follow-up, especially following COVID-19, where patients are more likely to notice changes in their sense of smell through increased self-awareness of symptoms. A previous study also reported a good correlation between VAS-reported OD and the BSIT, a validated psychophysical olfactory test (Prajapati et al. 2020). In our study, gustatory ratings had a moderate test-retest reliability and trigeminal had a poor test-retest reliability. This difference between chemosensory modalities was probably influenced by how well individuals understood the relation between the different sensations and each chemosensory modality. Indeed, the trigeminal system is a much less known system, and gustation is often mixed with retronasal olfaction (Deems et al. 1991, Spielman et al. 2004). It was reported that patients with self-reported gustatory function often had normal taste function following COVID-19 when tested with a validated psychophysical test (Boscolo-Rizzo et al. 2022b). In consequence, despite providing specific definitions and examples for all three chemosensory modalities prior to rating, awareness and accuracy were lower for gustation and trigeminal sensations, possibly demonstrating the need for patient's education when they present with chemosensory disorders.

Limitations

A major limitation of this study was the absence of a commonly used psychophysical test to assess the extent of chemosensory dysfunction. Therefore, our results obtained with the CPT were more difficult to compare directly with other studies using psychophysical testing and subject to various factors such as substance brand, expiration date and user. These results should therefore be interpreted with caution and not on an individual test result basis. Unfortunately, in clinical practice, psychophysical evaluations are seldom used for the diagnosis and follow-up of chemosensory impairments, which are mostly treated based on subjective assessments. While we encourage the use of validated psychophysical tests in primary care, neurology and ENT clinics, findings in this study confirmed a reliability of questioning olfactory functions subjectively especially in the context of follow-up of COVID-19 patients. An additional limitation of this study was the high prevalence of chemosensory disorders during the acute phase of COVID-19. Indeed, we observed higher participation rates among individuals with chemosensory disorders than those who have either recovered or simply never noticed any OD, GD or TD. Our study sample had a 20% higher rate of OD and GD, thus probably over estimating prevalence of chemosensory disorders at 11 months. Finally, the risk of recall bias is present, notably regarding sensitivity ratings, which is why we sought to compare answers from both questionnaires to assess the reliability of such measures.

Conclusion

In this study, there was limited improvement from 5 to 11 months after COVID-19 infection with a third of patients reporting persistent chemosensory dysfunctions. Prevalence of parosmia and phantosmia increased significantly from 5 to 11 months post-infection, possibly indicating changes in the olfactory epithelium. More studies on the physiopathology underlying post-COVID-19 OD are necessary to develop better treatments and interventions for the patients with persisting chemosensory dysfunctions.

Conflicts of interest

All authors have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. FGL is the recipient of a tier-2 Canada research Chair. No author declares any conflict of interest.

Acknowledgements and funding

We thank Josiane Rivard for preparing the online questionnaire and study participants. This work was supported financially by Fonds de recherche du Québec – Santé (chercheur boursier junior 2 #283144 to JF).

References

Aimrane, A., Laaradia, M. A., Sereno, D., Perrin, P., Draoui, A., Bougadir, B., Hadach, M., Zahir, M., Fdil, N., El Hiba, O., El Hidan, M. A. and Kahime, K. (2022). "Insight into COVID-19's epidemiology, pathology, and treatment." *Heliyon* **8**(1): e08799-e08799.

Allen, M., Poggiali, D., Whitaker, K., Marshall, T. R., van Langen, J. and Kievit, R. A. (2021). "Raincloud plots: a multi-platform tool for robust data visualization." *Wellcome Open Research* **4**(63).

Asadi, M. M., Shankayi, Z., Bahrami, F., Mohammadzadeh, T., Amini, H. and Naderi, M. (2021). "Quantitative analysis of taste disorder in COVID-19 patients, the hypersensitivity to salty quality." *New Microbes New Infect* **43**: 100919.

Biadsee, A., Dagan, O., Ormianer, Z., Kassem, F., Masarwa, S. and Biadsee, A. (2021). "Eight-month follow-up of olfactory and gustatory dysfunctions in recovered COVID-19 patients." *Am J Otolaryngol* **42**(4): 103065.

Boscolo-Rizzo, P., Guida, F., Polesel, J., Marcuzzo, A. V., Antonucci, P., Capriotti, V., Sacchet, E., Cagnolini, F., D'Alessandro, A., Zanelli, E., Marzolino, R., Lazzarin, C., Tofanelli, M., Gardenal, N., Borsetto, D., Hopkins, C., Vaira, L. A. and Tirelli, G. (2022a). "Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year prospective study." *Eur Arch Otorhinolaryngol* **279**(1): 515-520.

Boscolo-Rizzo, P., Hummel, T., Hopkins, C., D'Alessandro, A., Menini, A., Dibattista, M. and Tirelli, G. (2022b). "Comprehensive Chemosensory Psychophysical Evaluation of Self-reported Gustatory Dysfunction in Patients With Long-term COVID-19: A Cross-sectional Study." *JAMA Otolaryngol Head Neck Surg*.

Boscolo-Rizzo, P., Hummel, T., Hopkins, C., Dibattista, M., Menini, A., Spinato, G., Fabbris, C., Emanuelli, E., D'Alessandro, A., Marzolino, R., Zanelli, E., Cancellieri, E., Cargnelutti, K., Fadda, S., Borsetto, D., Vaira, L. A., Gardenal, N., Polesel, J. and Tirelli, G. (2021). "High prevalence of long-term olfactory, gustatory, and chemesthesia dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation." *Rhinology* **59**(6): 517-527.

Bussiere, N., Mei, J., Levesque-Boissonneault, C., Blais, M., Carazo, S., Gros-Louis, F., De Serres, G., Dupre, N. and Frasnelli, J. (2021). "Chemosensory Dysfunctions Induced by COVID-19 Can Persist up to 7 Months: A Study of Over 700 Healthcare Workers." *Chem Senses* **46**.

Cecchetto, C., Di Pizio, A., Genovese, F., Calcinoni, O., Macchi, A., Dunkel, A., Ohla, K., Spinelli, S., Farruggia, M. C., Joseph, P. V., Menini, A., Cantone, E., Dinnella, C., Cecchini, M. P., D'Errico, A., Mucignat-Caretta, C., Parma, V. and Dibattista, M. (2021). "Assessing the extent and timing of chemosensory impairments during COVID-19 pandemic." *Sci Rep* **11**(1): 17504.

Coelho, D. H., Reiter, E. R., Budd, S. G., Shin, Y., Kons, Z. A. and Costanzo, R. M. (2022). "Predictors of smell recovery in a nationwide prospective cohort of patients with COVID-19." *Am J Otolaryngol* **43**(1): 103239.

Croy, I., Nordin, S. and Hummel, T. (2014). "Olfactory disorders and quality of life--an updated review." *Chem Senses* **39**(3): 185-194.

Deems, D. A., Doty, R. L., Settle, R. G., Moore-Gillon, V., Shaman, P., Mester, A. F., Kimmelman, C. P., Brightman, V. J. and Snow, J. B., Jr. (1991). "Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center." *Arch Otolaryngol Head Neck Surg* **117**(5): 519-528.

Eliezer, M., Hamel, A. L., Houdart, E., Herman, P., Housset, J., Jourdaine, C., Eloit, C., Verillaud, B. and Hautefort, C. (2020). "Loss of smell in patients with COVID-19: MRI data reveal a transient edema of the olfactory clefts." *Neurology* **95**(23): e3145-e3152.

Ercoli, T., Masala, C., Pinna, I., Orofino, G., Solla, P., Rocchi, L. and Defazio, G. (2021). "Qualitative smell/taste disorders as sequelae of acute COVID-19." *Neurol Sci* **42**(12): 4921-4926.

Ferdenzi, C., Bousquet, C., Aguera, P. E., Dantec, M., Daude, C., Fornoni, L., Fournel, A., Kassan, A., Mantel, M., Moranges, M., Moussy, E., Richard Ortegon, S., Rouby, C. and Bensafi, M. (2021). "Recovery From COVID-19-Related Olfactory Disorders and Quality of Life: Insights From an Observational Online Study." *Chem Senses* **46**.

Fortunato, F., Martinelli, D., Iannelli, G., Milazzo, M., Farina, U., Di Matteo, G., De Nittis, R., Ascatigno, L., Cassano, M., Lopalco, P. L. and Prato, R. (2022). "Self-reported olfactory and gustatory dysfunctions in COVID-19 patients: a 1-year follow-up study in Foggia district, Italy." *BMC Infect Dis* **22**(1): 77.

Foster, K. J., Jauregui, E., Tajudeen, B., Bishehsari, F. and Mahdavinia, M. (2020). "Smell loss is a prognostic factor for lower severity of coronavirus disease 2019." *Ann Allergy Asthma Immunol* **125**(4): 481-483.

Havervall, S., Rosell, A., Phillipson, M., Mangsbo, S. M., Nilsson, P., Hober, S. and Thalin, C. (2021). "Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers." *JAMA* **325**(19): 2015-2016.

Haxel, B. R., Bertz-Duffy, S., Fruth, K., Letzel, S., Mann, W. J. and Muttray, A. (2012). "Comparison of subjective olfaction ratings in patients with and without olfactory disorders." *J Laryngol Otol* **126**(7): 692-697.

He, X., Cheng, X., Feng, X., Wan, H., Chen, S. and Xiong, M. (2020). "Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis." *Front Public Health* **8**: 561264.

Hopkins, C., Surda, P., Vaira, L. A., Lechien, J. R., Safarian, M., Saussez, S. and Kumar, N. (2021). "Six month follow-up of self-reported loss of smell during the COVID-19 pandemic." *Rhinology* **59**(1): 26-31.

Hopkins, C., Surda, P., Whitehead, E. and Kumar, B. N. (2020). "Early recovery following new onset anosmia during the COVID-19 pandemic - an observational cohort study." *J Otolaryngol Head Neck Surg* **49**(1): 26.

Huart, C., Philpott, C. M., Altundag, A., Fjaeldstad, A. W., Frasnelli, J., Gane, S., Hsieh, J. W., Holbrook, E. H., Konstantinidis, I., Landis, B. N., Macchi, A., Mueller, C. A., Negoias, S., Pinto, J. M., Poletti, S. C., Ramakrishnan, V. R., Rombaux, P., Vodicka, J., Welge-Luessen, A., Whitcroft, K. L. and Hummel, T. (2021). "Systemic corticosteroids in coronavirus disease 2019 (COVID-19)-related smell dysfunction: an international view." *Int Forum Allergy Rhinol* **11**(7): 1041-1046.

Iannilli, E., Leopold, D. A., Hornung, D. E. and Hummel, T. (2019). "Advances in Understanding Parosmia: An fMRI Study." *ORL J Otorhinolaryngol Relat Spec* **81**(4): 185-192.

Islek, A. and Balci, M. K. (2021). "Phantosmia with COVID-19 Related Olfactory Dysfunction: Report of Nine Case." *Indian J Otolaryngol Head Neck Surg*: 1-3.

Kakutani, Y., Narumi, T., Kobayakawa, T., Kawai, T., Kusakabe, Y., Kunieda, S. and Wada, Y. (2017). "Taste of breath: the temporal order of taste and smell synchronized with breathing as a determinant for taste and olfactory integration." *Sci Rep* **7**(1): 8922.

Koo, T. K. and Li, M. Y. (2016). "A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research." *J Chiropr Med* **15**(2): 155-163.

Kopishinskaia, S., Lapshova, D., Sherman, M., Velichko, I., Voznesensky, N. and Voznesenskaia, V. (2021). "Clinical Features in Russian Patients with COVID-Associated Parosmia/Phantosmia." *Psychiatr Danub* **33**(Suppl 9): 130-136.

Lechien, J. R., Chiesa-Estomba, C. M., Beckers, E., Mustin, V., Ducarme, M., Journe, F., Marchant, A., Jouffe, L., Barillari, M. R., Cammaroto, G., Circiu, M. P., Hans, S. and Saussez, S. (2021). "Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients." *J Intern Med* **290**(2): 451-461.

Lee, D. Y., Lee, W. H., Wee, J. H. and Kim, J. W. (2014). "Prognosis of postviral olfactory loss: follow-up study for longer than one year." *Am J Rhinol Allergy* **28**(5): 419-422.

Leopold, D. (2002). "Distortion of olfactory perception: diagnosis and treatment." *Chem Senses* **27**(7): 611-615.

Liu, D. T., Besser, G., Renner, B., Seyferth, S., Hummel, T. and Mueller, C. A. (2020). "Retronasal olfactory function in patients with smell loss but subjectively normal flavor perception." *Laryngoscope* **130**(7): 1629-1633.

Liu, D. T., Sabha, M., Damm, M., Philpott, C., Oleszkiewicz, A., Hahner, A. and Hummel, T. (2021). "Parosmia is Associated with Relevant Olfactory Recovery After Olfactory Training." *Laryngoscope* **131**(3): 618-623.

Lotsch, J. and Hummel, T. (2019). "Clinical Usefulness of Self-Rated Olfactory Performance-A Data Science-Based Assessment of 6000 Patients." *Chem Senses* **44**(6): 357-364.

Mehraeen, E., Behnezhad, F., Salehi, M. A., Noori, T., Harandi, H. and SeyedAlinaghi, S. (2021). "Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence." *Eur Arch Otorhinolaryngol* **278**(2): 307-312.

Mudatsir, M., Fajar, J. K., Wulandari, L., Soegiarto, G., Ilmawan, M., Purnamasari, Y., Mahdi, B. A., Jayanto, G. D., Suhendra, S., Setianingsih, Y. A., Hamdani, R., Suseno, D. A., Agustina, K., Naim, H. Y., Muchlas, M., Alluza, H. H. D., Rosida, N. A., Mayasari, M., Mustofa, M., Hartono, A., Aditya, R., Prastiwi, F., Meku, F. X., Sitio, M., Azmy, A., Santoso, A. S., Nugroho, R. A., Gersom, C., Rabaan, A. A., Masyeni, S., Nainu, F., Wagner, A. L., Dhama, K. and Harapan, H. (2020). "Predictors of COVID-19 severity: a systematic review and meta-analysis." *F1000Res* **9**: 1107.

Muller, A., Landis, B. N., Platzbecker, U., Holthoff, V., Frasnelli, J. and Hummel, T. (2006). "Severe chemotherapy-induced parosmia." *Am J Rhinol* **20**(4): 485-486.

NIH, N. I. o. H. (2022). "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines." Retrieved 2022-04-01, 2022, from <https://www.covid19treatmentguidelines.nih.gov/>.

Ohla, K., Veldhuizen, M. G., Green, T., Hannum, M. E., Bakke, A. J., Moein, S. T., Tognetti, A., Postma, E. M., Pellegrino, R., Hwang, L.-D., Albayay, J., Koyama, S., Nolden, A., Thomas-Danguin, T., Mucignat-Caretta, C., Menger, N. S., Croijmans, I., Öztürk, L., Yanik, H., Pierron, D., Pereda-Loth, V., Nunez-Parra, A., Pineda, A. M. M., Gillespie, D., Farruggia, M. C., Cecchetto, C., Fornazieri, M. A., Philpott, C., Voznessenskaya, V., Cooper, K., Dominguez, P. R., Calcinoni, O., de Groot, J., Boesveldt, S., Bhutani, S., Weir, E. M., Exten, C., Joseph, P. V., Parma, V., Hayes, J. E. and Niv, M. Y. (2021). "Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss." *medRxiv*: 2021.2008.21262763.

Otte, M. S., Bork, M. L., Zimmermann, P. H., Klussmann, J. P. and Luers, J. C. (2022). "Patients with COVID-19-associated olfactory impairment also show impaired trigeminal function." *Auris Nasus Larynx* **49**(1): 147-151.

Parma, V., Ohla, K., Veldhuizen, M. G., Niv, M. Y., Kelly, C. E., Bakke, A. J., Cooper, K. W., Bouysset, C., Pirastu, N., Dibattista, M., Kaur, R., Liuzza, M. T., Pepino, M. Y., Schopf, V.,

Pereda-Loth, V., Olsson, S. B., Gerkin, R. C., Rohlfs Dominguez, P., Albayay, J., Farruggia, M. C., Bhutani, S., Fjaeldstad, A. W., Kumar, R., Menini, A., Bensafi, M., Sandell, M., Konstantinidis, I., Di Pizio, A., Genovese, F., Ozturk, L., Thomas-Danguin, T., Frasnelli, J., Boesveldt, S., Saatci, O., Saraiva, L. R., Lin, C., Golebiowski, J., Hwang, L. D., Ozdener, M. H., Guardia, M. D., Laudamiel, C., Ritchie, M., Havlicek, J., Pierron, D., Roura, E., Navarro, M., Nolden, A. A., Lim, J., Whitcroft, K. L., Colquitt, L. R., Fermenzi, C., Brindha, E. V., Altundag, A., Macchi, A., Nunez-Parra, A., Patel, Z. M., Fiorucci, S., Philpott, C. M., Smith, B. C., Lundstrom, J. N., Mucignat, C., Parker, J. K., van den Brink, M., Schmuker, M., Fischmeister, F. P. S., Heinbockel, T., Shields, V. D. C., Faraji, F., Santamaria, E., Fredborg, W. E. A., Morini, G., Olofsson, J. K., Jalessi, M., Karni, N., D'Errico, A., Alizadeh, R., Pellegrino, R., Meyer, P., Huart, C., Chen, B., Soler, G. M., Alwashahi, M. K., Welge-Lussen, A., Freiherr, J., de Groot, J. H. B., Klein, H., Okamoto, M., Singh, P. B., Hsieh, J. W., Author, G. G., Reed, D. R., Hummel, T., Munger, S. D. and Hayes, J. E. (2020). "More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesia." *Chem Senses* **45**(7): 609-622.

Petrocelli, M., Cutrupi, S., Salzano, G., Maglitto, F., Salzano, F. A., Lechien, J. R., Saussez, S., Boscolo-Rizzo, P., De Riu, G. and Vaira, L. A. (2021). "Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study." *J Laryngol Otol* **135**(5): 436-441.

Prajapati, D. P., Shahrvini, B., MacDonald, B. V., Crawford, K. L., Lechner, M., DeConde, A. S. and Yan, C. H. (2020). "Association of subjective olfactory dysfunction and 12-item odor identification testing in ambulatory COVID-19 patients." *Int Forum Allergy Rhinol*.

Reden, J., Maroldt, H., Fritz, A., Zahnert, T. and Hummel, T. (2007). "A study on the prognostic significance of qualitative olfactory dysfunction." *Eur Arch Otorhinolaryngol* **264**(2): 139-144.

Saussez, S., Sharma, S., Thiriard, A., Olislagers, V., Vu Duc, I., Le Bon, S. D., Khalife, M., Hans, S., De Riu, G., Hopkins, C., Lechien, J. R., Vaira, L. A. and Marchant, A. (2021a). "Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction." *Eur J Neurol* **28**(11): 3702-3711.

Saussez, S., Vaira, L. A., Chiesa-Estomba, C. M., Bon, S. L., Horoi, M., Deiana, G., Petrocelli, M., Boelpaepe, P., Salzano, G., Khalife, M., Hans, S., De Riu, G., Hopkins, C. and Lechien, J. R. (2021b). "Short-Term Efficacy and Safety of Oral and Nasal Corticosteroids in COVID-19 Patients with Olfactory Dysfunction: A European Multicenter Study." *Pathogens* **10**(6).

Schwob, J. E., Costanzo, R. M. and Youngentob, S. L. (2020). Regeneration of the Olfactory Epithelium. *The Senses: A Comprehensive Reference*. B. Fritzsch. Oxford, Elsevier: 565-590.

Schwob, J. E., Jang, W., Holbrook, E. H., Lin, B., Herrick, D. B., Peterson, J. N. and Hewitt Coleman, J. (2017). "Stem and progenitor cells of the mammalian olfactory epithelium: Taking poietic license." *J Comp Neurol* **525**(4): 1034-1054.

Spence, C. (2015). "Just how much of what we taste derives from the sense of smell?" *Flavour* **4**(1): 30.

Spielman, A. I. and Lischka, F. W. (2004). Taste and Smell. *Encyclopedia of Gastroenterology*. L. R. Johnson. New York, Elsevier: 487-493.

Temmel, A. F., Quint, C., Schickinger-Fischer, B., Klimek, L., Stoller, E. and Hummel, T. (2002). "Characteristics of olfactory disorders in relation to major causes of olfactory loss." *Arch Otolaryngol Head Neck Surg* **128**(6): 635-641.

Tong, J. Y., Wong, A., Zhu, D., Fastenberg, J. H. and Tham, T. (2020). "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis." *Otolaryngol Head Neck Surg* **163**(1): 3-11.

Vaira, L. A., Hopkins, C., Petrocelli, M., Lechien, J. R., Cutrupi, S., Salzano, G., Chiesa-Estomba, C. M., Saussez, S. and De Riu, G. (2021a). "Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients." Rhinology **59**(1): 21-25.

Vaira, L. A., Salzano, G., Le Bon, S. D., Maglio, A., Petrocelli, M., Steffens, Y., Ligas, E., Maglitto, F., Lechien, J. R., Saussez, S., Varella, A., Salzano, F. A., Boscolo-Rizzo, P., Hopkins, C. and De Riu, G. (2021b). "Prevalence of Persistent Olfactory Disorders in Patients With COVID-19: A Psychophysical Case-Control Study With 1-Year Follow-up." Otolaryngol Head Neck Surg **0**(0): 1945998211061511.

Welge-Lussen, A. and Wolfensberger, M. (2006). "Olfactory disorders following upper respiratory tract infections." Adv Otorhinolaryngol **63**: 125-132.

Xydakis, M. S., Albers, M. W., Holbrook, E. H., Lyon, D. M., Shih, R. Y., Frasnelli, J. A., Pagenstecher, A., Kupke, A., Enquist, L. W. and Perlman, S. (2021). "Post-viral effects of COVID-19 in the olfactory system and their implications." The Lancet Neurology **20**(9): 753-761.

List of tables:

Table 1. Self-reported and semi-objectively measured chemosensory alterations. T1: during SARS-CoV-2 infection; T2: approximately 5 months after SARS-CoV-2 infection; T3: approximately 11 months after SARS-CoV-2 infection; Q1: Questionnaire, sent at T2; Q2: questionnaire sent at T3; OD: Olfactory dysfunction; GD: Gustatory dysfunction.; CPT: Chemosensory Perception Test; INSPQ: Institut National de santé publique du Québec.

	Prevalence of self-reported OD in INSPQ study n (%)	Prevalence of self-reported GD in INSPQ study n (%)	Reduced olfactory sensitivity n (%)		Reduced gustatory sensitivity n (%)		Reduced trigeminal sensitivity n (%)		OD measured by CPT n (%)	Impaired olfactory function n (%)	Impaired gustatory function n (%)	Impaired trigeminal function n (%)
			Q1	Q2	Q1	Q2	Q1	Q2				
N	4542										366	
T1	2966 (65.3)	2748 (60.5)	307 (83.9)	306 (83.6)	301 (82.2)	297 (81.1)	175 (47.8)	196 (53.6)				
T2			155 (56.2) *	242 (66.1)	123 (44.6) *	224 (61.2)	66 (23.9) *	133 (36.3)	108 (29.5)			
T3			184 (50.3)		163 (44.5)		86 (23.5)		91 (24.9)	118 (32.2)	111 (30.3)	52 (14.2)

*n=276

Table 2. Logistic regression model predicting persisting olfactory dysfunction at 11 months following COVID-19 (n= 307).

	Variable	b	P	95% C.I. for Odds Ratio		
				Lower	Odds Ratio	Upper
Variables included	Chest pain during COVID-19	0.563	<.001	1.05	1.76	2.94
	Dysgeusia during COVID-19	0.856	.007	1.26	2.35	4.39
	Phantosmia at 5 months	0.754	.030	1.08	2.13	4.20
Variables excluded	Sex	-	0.789	-	-	-
	Olfactory sensitivity rating before COVID-19	-	0.553	-	-	-
	Participant age	-	0.755	-	-	-
	Fever during COVID-19	-	0.299	-	-	-
	Dry cough during COVID-19	-	0.214	-	-	-
	Productive cough during COVID-19	-	0.933	-	-	-
	Dyspnea during COVID-19	-	0.405	-	-	-
	Rhinorrhea during COVID-19	-	0.520	-	-	-
	Odynophagia during COVID-19	-	0.338	-	-	-
	Appetite loss during COVID-19	-	0.923	-	-	-
	Headache during COVID-19	-	0.447	-	-	-
	Myalgia during COVID-19	-	0.111	-	-	-
	Fatigue during COVID-19	-	0.928	-	-	-
	Diarrhea during COVID-19	-	0.326	-	-	-
	Abdominal pain during COVID-19	-	0.211	-	-	-
	Nausea during COVID-19	-	0.448	-	-	-
	Parosmia at 5 months	-	0.707	-	-	-
	Hypertension	-	0.510	-	-	-
	Obesity	-	0.447	-	-	-

Table 3. Intraclass correlation coefficients and Spearman's correlation coefficients for olfactory, gustatory, and trigeminal subjective ratings at 5 and 11 months.

	Olfaction		Gustation		Trigeminal	
	ICC* (95% CI)	Spearman's	ICC* (95% CI)	Spearman's	ICC* (95% CI)	Spearman's
T0 Before COVID (n=366)	0.635 (0.552 - 0.703)	0.577**	0.332 (0.180 - 0.456)	0.539**	0.388 (0.248 - 0.502)	0.379**
T1 During COVID (n=366)	0.927 (0.908 - 0.941)	0.816**	0.809 (0.865 - 0.910)	0.796**	0.607 (0.515 - 0.681)	0.446**
T2 At 5 months (n= 276)	0.818 (0.760 - 0.860)	0.701**	0.661 (0.494 - 0.764)	0.579**	0.320 (0.143 - 0.461)	0.346**

*Two-way mixed effects, absolute agreement, single rater

** P < .001

List of figures:

Figure 1. Participant inclusion flow chart. INSPQ : Institut national de santé publique du Québec

Figure 2. Tendency plots for self-reported chemosensory ratings at 5 months and 11 months following COVID-19 infection.

Comparing self-reported chemosensory scores collected at the 5- and 11-month questionnaires. T2, Q1: 5-month rating at the 5-month questionnaire; T3, Q2: 11-month rating at the 11-month questionnaire.

Figure 3. Density distributions of self-reported chemosensory ratings. (n= 366)

Raincloud plot representing self-reported scores for olfaction (A), gustation (B), and trigeminal (C) function before (T0), during (T1) and 5 (T2) and 11 (T3) months after COVID-19. Ratings from individual participants are displayed as dots. Boxplots show the first to third quartiles, horizontal line denotes the median, and whiskers denote 1.5 times interquartile range. Compared to baseline, self-reported scores of olfaction, gustation and trigeminal function were significantly lower during COVID-19 and have not fully returned to baseline values 11 months after COVID-19.

Figure 4. Status of subjective chemosensory function at 11 months compared to before COVID-19. (n= 366)